Bionomics Limited (BNOX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BNOX
- Company Bionomics Limited
- Price $0.28
- Changes Percentage -43.43
- Change -0.2141
- Day Low $0.25
- Day High $0.44
- Year High $2.84
- Year Low $0.18
- Market Cap $1,873,849
- Price Avg 50 EMA (D) $0.45
- Price Avg 200 EMA (D) $0.79
- Exchange NASDAQ
- Volume 17,050,060
- Average Volume 8,579,331
- Open $0.42
- Previous Close $0.49
- EPS -1.8
- PE -0.15
- Earnings Announcement 2025-02-20 12:00:00
- Shares Outstanding $6,718,713
Company brief: BIONOMICS LIMITED (BNOX )
- Healthcare
- Biotechnology
- Dr. Spyridon Papapetropoulos M.D., Ph.D.
- https://www.bionomics.com.au
- AU
- N/A
- 12-16-2021
- US09063M2052
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.